Key advancements in Verrica’s pipeline include positive data from a Phase 2 study of VP-315, an oncolytic peptide candidate targeting basal cell carcinoma. Additionally, the company plans to ...

VP-315 is described as a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy that could induce ...

This article focuses on one of those potential combination therapies: oncolytic viruses (OVs). In the tug-of-war between fire (immune stimulation) and ice (immune suppression), ice usually wins ...

Other proteins such as H-Ras and Rac1 have been shown to mediate oncolytic specificity in certain systems. The NDV genome allows for stable expression of foreign genes while avoiding the problem ...

Lytix’ technology is based on research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. VP-315 is a first-in-class molecule representing a new ...

Bacillus Calmette-Guérin (BCG) remains the primary treatment for patients with high-risk bladder cancer, but resistance develops in 30% to 40% of cases. The use of oncolytic viruses has emerged as a ...

The financing will enable the completion of a Phase 1B clinical trial of its lead tumour antigen-coated oncolytic virus candidate, PeptiCRAd-1, in Germany, Italy, and Australia. At Johnson & Johnson ...